U.S. Justice Dept seeks more details on $8 billion CVS-Signify Health deal
Reuters
Published Oct 20, 2022 07:06AM ET
Updated Oct 20, 2022 04:22PM ET
(Reuters) -The U.S. Department of Justice has asked for more details on CVS Health Corp (NYSE:CVS)'s proposed $8 billion deal to buy Signify Health, in a possible indication that the companies face a longer deal investigation rather than a quick approval.
The deal, announced last month, was expected to face a tough antitrust review even though the two companies do not compete directly in any market, according to experts.
Large mergers and acquisitions have come under intense antitrust scrutiny, and lowering healthcare costs has been an important strategic mission for the Biden Administration.
UnitedHealth Group (NYSE:UNH) earlier this month completed its acquisition of Change Healthcare (NASDAQ:CHNG), after over a year of antitrust scrutiny.
Acquiring Signify Health will enable CVS, which operates a pharmacy chain, a health insurance business and offers pharmacy benefit management services, to provide further care management for at-home patients.
The deal is expected to close in the first half of 2023, CVS said in a filing on Thursday.
Signify offers technology and analytics to help with at-home care for patients. It has said its services can help identify potential health risks and gaps in care.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.